Related Experiment Video
Updated: Jul 20, 2025
13:24
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
11.9K
The New NCI Precision Medicine Trials
Lyndsay N Harris1, Charles D Blanke2, Harry P Erba3
1Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.
Summary
Master protocols like NCI-MATCH advanced precision oncology. Newer NCI trials (ComboMATCH, iMATCH, myeloMATCH) explore targeted therapy combinations to improve metastatic disease control in cancer.
Area of Science:
- Oncology
- Precision Medicine
- Clinical Trial Design
Background:
- Master protocols, including basket, umbrella, and platform trials, have gained prominence for studying precision medicine in oncology over the past decade.
- First-generation trials, such as NCI-MATCH (Molecular Analysis for Therapy Choice), demonstrated the feasibility of large-scale targeted therapy research from both laboratory and clinical viewpoints.
- Single-agent targeted therapies have demonstrated limited efficacy in controlling metastatic cancer, even with precise drug-target matching.
Purpose of the Study:
- To introduce and discuss the design and necessary infrastructure for three second-generation precision medicine trials initiated by the NCI.
- To address the limitations of single-agent targeted therapies by exploring newer approaches involving combinations of targeted therapies or targeted therapy with standard treatments.
- To advance the field of precision oncology by developing innovative clinical trial designs for combination therapies.
Main Methods:
- Discussion of the design principles behind the new NCI-led precision medicine trials: ComboMATCH, iMATCH, and myeloMATCH.
- Exploration of the infrastructure requirements for implementing these complex, multi-arm, multi-stage trial designs.
- Focus on the strategic shift towards combination therapies within a master protocol framework.
Main Results:
- The abstract does not present specific results but discusses the rationale and design of new trials.
- Highlights the transition from first-generation single-agent targeted therapy trials to second-generation combination therapy trials.
- Emphasizes the feasibility and necessity of advanced master protocol designs for future precision oncology research.
Conclusions:
- Second-generation precision medicine trials are essential to overcome the limitations of single-agent therapies in metastatic cancer.
- The NCI's new trials (ComboMATCH, iMATCH, myeloMATCH) represent a significant step forward in master protocol design for combination therapies.
- Effective infrastructure and innovative trial designs are crucial for the successful implementation of large-scale precision oncology studies.
Related Concept Videos
01:16Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K